BRAF and colorectal carcinoma: In this study, the MST after the initial treatment to stage IV or recurrence was 13 months in BRAF-mutant patients with CRC who had extra-ovarian metastases only; however, the MST after the initial treatment to stage IV or recurrence reached 22 months in BRAF-mutant patients with ovarian metastases.